Summary VLA2 is thought to be involved in the metastatic process in malignant tumours, in particular in carcinomatous cell adhesion to vessel basement membrane. VLA2 expression was immunohistochemically investigated in 204 breast carcinomas. Frozen tissue sections were probed with monoclonal anti-VLA2 using automated (Ventana ES 320 System) and quantitative (SAMBA 2005 and P-glycoprotein (P-gp) (P < 0.01) and inversely correlated with cathepsin D (P < 0.001), but was independent of Ki67/MIB1, p53, bcl-2, c-erbB-2, E cadherin, CD44v, CD31, cestrogen and progesterone receptors' (ER, PR) antigenic sites and pS2. The exact role, if any, of VLA2 in tumour cell dissemination remains to be elucidated and the clinical relevance of VLA2 immunodetection in breast carcinomas requires further investigation of the correlation between VLA2 immunocytochemical expression and patients' outcome and response to chemotherapy.
The integrins are heterodimers consisting of non-covalently associated ox and P subunits that mediate cell adhesion. As originally described (Hynes, 1987) , integrins were divided into three subfamilies, each with a common 3 subunit capable of associating with a specific group of ox subunits. In fact, there are several different : subunits, and x subunits can combine with more than one subunit (see review in Pignatelli, 1994) .
Because of the complexity of the integrins family, it proves useful to group integrins according to their cell binding activity. Integrins can be segregated into three groups: those that function as cell-cell adhesion molecules, those that bind primarily to the major constituents of the basement membrane (i.e. collagen and laminin) and those that bind primarily to the extracellular matrix proteins found during early development, inflammation and wound healing (i.e. fibronectin, fibrinogen vitronectin and thrombospondin) (see review in Albelda, 1993) .
The a, ,B integrin (or VLA2, very late antigen) is a receptor (145-kDa molecule) for collagen and laminin that is expressed in many tumour cell lines (see review in Albelda, 1993) . In addition, VLA1 is widely expressed in normal tissue and its polarized distribution in various epithelial cells suggests that they may significantly act upon the control of cellular growth and differentiation (De Strooper et al, 1989; Ruoslahi, 1991) . Also VLA, is probably implicated in the complex multistep suggesting that increased adhesion of tumour cells to subendothelial basement membrane components results in increased metastatic potential. In contrast, the down-regulation of VLA, is observed in poorly differentiated or larger tumours of the colon (Pignatelli et al, 1991a) , liver (Patriarca et al, 1993) , skin (Stamp et al, 1991) and breast Pignatelli et al, 1991b; Arihiro et al, 1993) , and in prostate carcinomas (Bonkhoff et al, 1993) and melanomas (Schadendorf et al, 1993) , suggesting that reduced VLA2 expression may be an indicator of predisposition to the development of metastases.
However, adhesion of tumour cells to basement membrane components is not the only process thought to be involved in tumour growth and metastasis Albelda, 1993; Pignatelli et al, 1994) . Tumour metastasis requires: firstly, the release of the cells from the primary tumour with decreased cell-cell adhesion and reduced cell adhesion to epithelial basement membrane; secondly, the migration of tumour cells and their adhesion to extracellular matrix; and, finally, their penetration into the vessels' walls and their arrest in the microcirculation of the distant organs, and adhesion to endothelial cells and vessel basement membrane before extravasation Albelda, 1993; Pignatelli et al, 1994) .
In this study, our goal was to investigate the relationship between the tumour cells' capacity to bind to basement membrane molecules, reflected by VLA, expression, and other steps of the metastatic process involving several other adhesive molecules or proteases, including E cadherin (cell-cell adhesion), cathepsin D VLA2 immunodetection in breast carcinomas 2275 (facilitating the migration in extracellular matrix), VLA3 and CD44 (adhesion to extracellular components), CD31 (angiogenesis), VCAM and ELAM (endothelial cell activation). We investigated a series of 204 breast carcinomas using automated immunohistochemistry (Ventana ES 320 device) and quantification of the immunoprecipitates by processing digitized microscopic images (SAMBA 2005 System). In addition, our objective was to investigate the prognostic significance of VLA, immunohistochemical expression in tumour cells by correlating the results with current histoprognostic indicators (tumour size, grade, type and axillary node status) and with immunohistochemical indicators of high degree of cell proliferation (MIB l/Ki67, p53, bcl-2, c-erbB-2).
MATERIALS AND METHODS Source of tissue samples
The specimens were surgically obtained from 204 patients with breast carcinomas, from January 1993 to May 1994. Mean age was 56.4 years (range 32-83 years, median 56 years). For all patients, surgical resection was the primary treatment, and none received irradiation or chemotherapy preoperatively. Surgical specimens were fixed in Bouin fixative, paraffin embedded and haematoxylin-eosin-and saffronin-stained for routine microscopic diagnosis. Samples for immunodetection were taken from the representative cancerous lesions by pathologists, in the same way as for the sample used for the intraoperative microscopic diagnosis on frozen sections. Tissue samples for immunodetections were promptly dipped in liquid nitrogen and stored frozen at -800C in the tumour library of the laboratory.
Histopathological features
Tumour sizes ranged from 4 to 80 mm (mean 17.9; s.d. 12.24). In 196 of 204 cases, axillary lymph node resection was performed and 62% of patients (n = 121) were node positive and 38% (n = 75) were node negative.
All carcinomas were invasive. Invasive ductal carcinomas accounted for 74% (145 of 204), lobular carcinomas for 17% (38 of 204) and invasive carcinomas of other types for 9% (20 of 204) .
Tumours were graded according to Elston's grading system (Elston et al, 1991) . Grade I tumours accounted for 22% (45 of 204) , grade II for 54% (109 of 204) and grade III for 24% (49 of 204) . Carcinomas were also graded according to Le Doussal's modified Bloom's grading system (Le Doussal et al, 1989) in five grades: 8% of grade I, 30% of grade II, 31% of grade III, 27% of grade IV and 4% of grade V. Tumours were also ranked according to the Nottingham prognostic index (Galea et al, 1992) , which ranged from 2.1 to 8 (mean 4.1; s.d. 1.22). Tumours were aneuploid in 58% of the cases (97/168), with a variable degree of hyperploidy (mean 5.4%, range 0-60%) (cell imprints, Feulgen staining, image analysis) (Charpin et al, 1990 (Charpin et al, , 1992 .
Immunohistological staining procedures
Antibody sources Anti-human VLA, (150-kDa integrin oc2 chain, anti-CD29b) mouse monoclonal (immunoglobulin G1) antibody (clone Gi9) was purchased from Immunotech (Marseille, France) and used diluted at 1:500 (Arihiro et al, 1993; Bonkhoff et al, 1993) . The other monoclonal antibodies used were all commercially available and were used as described previously (Charpin et al, 1988a (Charpin et al, , 1994 (Charpin et al, , 1995b (Charpin et al, , 1997a Automated immunohistochemistry Automated immunohistochemistry was used for all the monoclonal antibodies, except for anti-E cadherin (LSAB kits, Dako) (Charpin et al, 1997c ) and anti-ER and anti-PR (Abbott Kits) (Charpin et al, 1988b ) and was performed on consecutive sections (4 gm thick) with avidin-biotin-peroxidase complex on Ventana 320 device (Grogan et al, 1993 (Grogan et al, , 1995 (Charpin et al, 1997a-d) . The two parameters of densitometric analysis, percentage of immunostained surface (compared with counterstained surface) and mean optical density (MOD), which reflects the staining intensity (on SAMBA arbitrary units scale of 0-255) were obtained as previously reported (Charpin et al, 1988a (Charpin et al, and b, 1994 (Charpin et al, , 1995a (Charpin et al, and b, 1996a (Charpin et al, and b, 1997a 
Correlation of VLA2 expression with quantitative immunodetection Distribution
The distribution of the antigens, investigated using the same method as that for VLA2 on serial sections, was first studied by The results of quantitative evaluation of growth fraction (MIB 1) and immunoreaction with anti-p53, anti-bcl-2, anti-c-erbB-2 protein, anti-cathepsin D, anti-CD3 1, anti-CD44v, anti-cadherin, anti-VCAM, anti-ELAM, anti-VLA3, anti-P-gp, anti-ER and -PR antigenic sites, and anti-pS2 in VLA2 -positive and -negative tumours are shown in Table 2 .
Correlation (Spearman's and Kendall's tests) VLA2 expression in breast carcinomas was independent of most of the other antigens investigated (Table 3) . However, a significant correlation was observed between VLA2 immunohistochemical expression and that of P-gp, VCAM, ELAM and VLA3 (Tables 3  and 4 ) and was inversely correlated with cathepsin D. . Various molecules, especially adhesion molecules, are involved at the different steps of the metastatic process and are expressed on tumour cells or released in the extracellular compartment Albelda, 1993; Pignatelli and Vessey, 1994) . Thus their immunodetection in tissue sections may be a relevant tool useful in clinical practice to identify patients with significant risk of developing metastatic disease, promoted by the variations in the expression of the adhesive molecules. However, the practical relevance of immunohistochemistry can be determined provided that the technical procedures are as far as possible standardized and provided that methodological bias are optimally reduced. Methodological bias may result from several factors. Firstly, tissue fixation and paraffin embedding may be the source of antigen damage. Although recent advances in immunohistochemistry have shown the suitability of archival paraffin tissue blocks for immunodetection after antigen retrieval (microwave), the freezing of tissue blocks, when possible, basically does not modify the structure of antigens in tissues. Secondly, inconsistencies may result from variations in the immunohistochemical methods used. In this regard, an automated device rather than in-house manual procedures provides a better guarantee of quality control, particularly with regard to reproducibility. Finally, analytical bias may result from the method used for the evaluation of the results. Semiquantitative analysis of the immunoprecipitates in tissue sections is convenient, rapid and cost effective, but its reliability hinges on observers' experience and reproducibility. Although semiquantitative evaluation is obviously sufficient to differentiate negative vs positive reaction, it is not accurate enough to evaluate intermediate patterns of staining. In contrast, quantitative analysis by computerized processing of digitized microscopic images provides more objective data, and variations in staining are more accurately evaluated. In addition, the numeric values of parameters are more suitable for statistical analysis. In the present study, we evaluated VLA, in optimal technical conditions using frozen tissue sections, automated immunohistochemistry and computerized analysis of digitized microscopic images, as previously used for other molecules (Charpin et al, 1988a (Charpin et al, and b, 1994 (Charpin et al, , 1995a (Charpin et al, and b, 1996b (Charpin et al, , 1997a .
Adhesion molecules are involved in the cascade of events of the metastatic disease. Some are involved in cell-cell adhesion or in cell adhesion to epithelial basement membrane. Some are involved in adhesion to extracellular matrix and others in adhesion to the vessel wall either to activate endothelial cells or to increase binding to vessel basement membrane. VLA, which is an o2 P1 integrin acting as a receptor for collagen and laminin, is involved in cell binding to epithelial basement membrane and also to the vessel basement membrane. These adhesive properties of tumour cells expressing VLA, promote the development of metastases as shown by experimental data (Chan et al, 1991) and facilitate adhesion to the vessel wall. However, the decreased expression of VLA, in human carcinomas ; Pignatelli et al, 1991a and b; Stamp and Pignatelli, 1991; Arihiro et al, 1993; Bonkhoff et al, 1993; Patriarca et al, 1993 ) is associated with higher metastatic rate or tumour dedifferentiation. In this respect, the VLA, expression of tumour cells in early breast carcinomas could constitute a prognostic indicator.
Using optimal technical conditions (not comparable to previous studies for VLA, immunodetection) in our series of breast carcinomas, we did not observe any significant relationship between VLA, expression and current histoprognostic indicators, such as tumour size, grade, type, degree of tumour aneuploidy and hyperploidy, or the axillary node status and the Nottingham prognostic index. These results suggest that in order to determine its exact prognostic relevance, the significance of VLA, expression in VLA2immunodetection in breast carcinomas 2279 breast carcinomas requires further investigation, using the same method, taking into account correlation with the patients' outcome. The adhesive properties of tumour cells probably depend on the expression of adhesion molecules, which may vary independently or concomitantly. VLA2 expression by tumour in breast carcinomas seems to be independent of cell-cell adhesion or adhesion to extracellular matrix, as VLA2 immunostaining was independent of E cadherin or of CD44 v6 expression detected using the same method (Charpin et al, 1997b and c) . However, VLA2 significantly correlated with VLA3 (P < 0.01), a receptor for fibronectin that also belongs to the integrin group and that may have similar regulation mechanisms.
We found that VLA, expression was inversely correlated with cathepsin D expression in tumour sections, suggesting that the decreased capacity of tumour cells to bind to basement membrane is associated with an increased capacity of tumour cell migration in the extracellular matrix, facilitated by proteases that they produce. Thus, VLA2 and D cathepsin seem to concomitantly promote tumour progression.
Angiogenesis in breast carcinomas favours tumour growth and facilitates entry into the circulation (Folkman, 1971; Liotta et al, 1974) , and vessel counts and immunohistochemical labelling of vessels and endothelial cells have been shown to be endowed with some clinical relevance (Weidner, 1991; Charpin et al, 1997a) . Our results show that VLA2 immunocytochemical expression is independent of that of CD31, which reflects tumour stromal angiogenesis (Charpin et al, 1995b) . However, VLA2 was found to correlate (P < 0.01) with the expression of VCAM (IGSF) and ELAM (E-selectin) in tumours reflecting the activation of endothelial cells. This suggests that the increased expression of ELAM or VCAM molecules, which are receptors for ligands expressed on the surface of tumour cells, such as Sialyl Lewisx determinants (Walz et al, 1990; Tiemeyer et al, 1991) or VLA4 (Albelda et al, 1990; Elices et al, 1990; Gelhsen et al, 1992) , correlates with the capacity of tumour cells, to bind vessel basement membranes through VLA2 expression.
Some experimental studies have shown that collagen-induced morphogenesis and expression of o2 integrin subunit is inhibited in c-erbB-2-transfected MTSV 1-7 human mammary epithelial cells (D'Souza et al, 1993) , suggesting that in human breast carcinomas the expression of c-erbB-2 product could correlate with integrin expression. However, in our study, VLA2 / ox2 1 integrin did not significantly correlate with c-erbB-2, both molecules being detected according to the same immunohistochemical procedures on consecutive sections.
Recently, we also used this method to detect p53, bcl-2 and Ki67 antigens in breast carcinomas (Charpin et al, 1996a, 1997b and . These antigens have been reported to correlate with tumour growth and tumour cell proliferative activity. Similar to C-erbB2 expression, the expression of these molecules did not correlate with VLA2 expression, suggesting that cell proliferation and adhesive properties are regulated differently.
In conclusion, our results show that VLA2 immunohistochemical expression in breast carcinomas is independent of most current histoprognostic indicators and of the tumour cells expression of some adhesion molecules, such as E cadherins. However, VLA, expression correlates with the expression in tumours of adhesion molecules of the same family, such as VLA3 integrin or another family, such as E-selectin (ELAM) or IGSF (VCAM).
The prognostic significance of VLA2 expression in tumours remains to be demonstrated by correlations with the patients' outcome.
